AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Female gender.
* Age \>35 years.
* Initiation of treatment with a GLP-1/GIP agonist, or treatment duration \< 3 months, as per routine clinical practice in the endocrinology clinic.
* Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
* Additional criteria to be included by the client.
Exclusion Criteria:
* Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
* Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
* Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
* Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
* Women who have used anti-hair loss products within the last 3 months.
* Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, …